Fig. 1From: Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumorsPatient disposition. CRC, colorectal cancer; dMMR, defective mismatch repair; GC, gastric cancer; MSI-H, microsatellite instability high; PEP, primary efficacy populationBack to article page